Drug Profile
SNG 12
Alternative Names: SNG-12; SynapsinaeLatest Information Update: 23 Sep 2022
Price :
$50
*
At a glance
- Originator SyneuRx International (Taiwan) corp
- Class Antidepressants
- Mechanism of Action Glycine transporter 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dementia; Psychotic disorders
Most Recent Events
- 23 Sep 2022 SyneuRx International submits IND application to the US FDA for a planned phase III trial in Depressive disorders and Suicidal ideation, prior to September 2022 (SyneuRx pipeline, September 2022)
- 23 Sep 2022 The US FDA approves IND application of SyneuRx for a planned phase III trial in Depressive disorders and Suicidal ideation, prior to September 2022 (SyneuRx pipeline, September 2022)
- 18 Apr 2022 Phase-II clinical trials in Dementia in USA (unspecified route) (Syneux pipeline, April 2022)